Compare stocks

Pentixapharm Holding AG is a clinical-stage biopharmaceutical company specializing in the development of targeted radiopharmaceuticals for diagnostic and therapeutic applications. Its core products include PentixaFor, a Gallium-68-based tracer for diagnosing hematological and solid tumors, and PentixaTher, a Yttrium-90-based therapeutic agent for treating non-Hodgkin lymphomas. Founded in 2019 and headquartered in Berlin, Germany, the company operates additional offices in Würzburg. In July 2024, Pentixapharm acquired Glycotope's target discovery business, enhancing its pipeline with preclinical antibodies against multiple oncology targets. The company's strategic focus on CXCR4 ligand-based radiopharmaceuticals positions it to address a range of cancers and other diseases. (,)

AbbVie is a pharmaceutical firm with a strong exposure to immunology (with Humira, Skyrizi, and Rinvoq) and oncology (with Imbruvica and Venclexta). The company was spun off from Abbott in early 2013. The 2020 acquisition of Allergan added several new products and drugs in aesthetics, including Botox. The 2024 acquisitions of Cerevel (neuroscience) and ImmunoGen (oncology) help supplement AbbVie's portfolio, while the 2026 acquisition of Apogee adds to AbbVie's immunology depth.